Stability of rifabutin in two extemporaneously compounded oral liquids

American Journal of Health-System Pharmacy

Volumn 56, Issue 4, 1999, Pages 333-336

  Haslam, John L ^a   Egodage, Kamal L ^a   Chen, Yingxue ^b   Rajewski, Roger A ^b   Stella, Valentino ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b NONE

Author keywords

Antituberculars; Capsules; Cherry syrup; Compounding; Formulations; Incompatibilities; Rifabutin; Stability; Storage; Suspending agents; Suspensions; Sweetening agents; Temperature

Indexed keywords

ANSAMYCIN DERIVATIVE; DRUG VEHICLE; ORA PLUS; ORA SWEET; RIFABUTIN; RIFAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MYCOBACTERIOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUSPENSION; SYRUP; TEMPERATURE;

EID: 0033557183     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.4.333     Document Type: Article

References (5)

1. The Merck index. 11th ed. Rifabutin. Rahway, NJ: Merck & Co.; 1996:1413.
2. Mycobutin package insert. Columbus, OH: Adria Laboratories; 1996 Apr.
3. Allen LV Jr. Vehicles for liquid oral dosage forms. US Pharm. 1991; 16(9):72-6,80.
4. Dawson LM, Nahata MC. Guidelines for compounding oral medications for pediatric patients. J Pharm Technol. 1991; 7(Sep-Oct):168-75.
5. The United States pharmacopeia, 23rd rev., and The national formulary, 18th ed. Second supplement. Rockville, MD: United States Pharmacopeial Convention; 1995 May 15:2674-5.